Roundtable on Women’s Health Innovation

GHIF II is now live and actively fundraising to ensure continued support to Raydiant.

This roundtable brought together key leaders in women’s health innovation. The session brought together key voices advancing innovation in women's health across capital, clinical, and technology ecosystems — including representatives from GHIF, CBIV, and UCSF.

• Sheetal Nariani, General Partner & CFO, GHIF

• Dr. Janet Moore Goldman, Maternal-Fetal Medicine Specialist, UCSF

• Annie Thériault & Megan Dover, Managing Partners, Cross-Border Impact Ventures

Key Takeaways:

• Massive innovation gap: For decades, pregnant women were excluded from clinical trials. This is only now being addressed with inclusive design, research, and technology.

• High investor interest: Despite historical underfunding, femtech is showing strong deal flow, with key focus areas like maternal health, menopause, and fertility access.

• Strong M&A appetite: Strategic acquirers are actively seeking innovations in maternal and women's health, from diagnostics to AI-based tools.

• Next-gen solutions: From predictive ultrasound tech to at-home monitoring and inclusive cancer diagnostics, startups are solving urgent and overlooked problems.

• Platform plays matter: Investors are prioritizing scalable, multi-product solutions with the potential for significant impact and venture-level returns.

GHIF II will continue investing in bold innovations that transform women’s health — with a focus on underserved markets, inclusive product development, and measurable patient outcomes.